{"id":529803,"date":"2021-02-10T19:52:01","date_gmt":"2021-02-10T19:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529803"},"modified":"2021-02-10T19:52:01","modified_gmt":"2021-02-10T19:52:01","slug":"malt-lymphoma-market-insights-drug-and-market-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/malt-lymphoma-market-insights-drug-and-market-forecast-by-delveinsight_529803.html","title":{"rendered":"MALT Lymphoma Market Insights, Drug and Market Forecast by DelveInsight"},"content":{"rendered":"
\"MALT<\/a><\/div>\n

DelveInsight has launched a new report on MALT Lymphoma Market<\/a><\/strong><\/p>\n

 <\/p>\n

Lymphoma is the cancer of the lymphatic system. The lymphatic system is a network of thin tubes and lymph nodes that run throughout the body. Primary gastric lymphoma (PGL) is the most common extranodal site of non-Hodgkin lymphoma and represents 30–40% of all extranodal lymphomas. It also represents 4–20% of all non-Hodgkin lymphomas (NHL) and approximately 5% of primary gastric neoplasms. The frequent histological subtypes of PGL are marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL).<\/p>\n

 <\/p>\n

Request for free sample copy- https:\/\/www.delveinsight.com\/sample-request\/malt-lymphoma-market <\/a><\/strong><\/p>\n

 <\/p>\n

The MALT Lymphoma market <\/strong>report<\/strong> provides an edge while developing business strategies, by understanding trends shaping and driving the MALT Lymphoma market <\/strong>report<\/strong><\/p>\n

 <\/p>\n

MALT Lymphoma<\/strong> Treatment Market<\/strong><\/p>\n

MALT stands for mucosa-associated lymphoid tissue. The mucosa is the moist tissue that lines some organs and body cavities, including the nose, mouth, lungs, and digestive tract; thus, MALT lymphoma starts in the body organs, and not in the lymph nodes.<\/p>\n

 <\/p>\n

MALT Lymphoma Symptoms<\/strong><\/p>\n

 The main symptoms are nonspecific and include fatigue, fever, nausea, constipation, weight loss, and anemia. Other symptoms depend on the affected organs: abdominal pain in cases with gastric involvement, recurrent respiratory infections in cases with pulmonary involvement, and visual impairment in cases with lacrimal gland involvement. In general, patients do not have lymphadenopathy.<\/p>\n

 <\/p>\n

MALT Lymphoma Market Disease<\/strong><\/p>\n

Diagnosis is based on histology of the lesion, as in all lymphomas, a complete blood count and biochemical analysis. Endoscopic examination is required for gastrointestinal or pulmonary lymphoma. MRI and CT scanning are required to determine the stage of the disease. Bone marrow biopsy is also performed.<\/p>\n

 <\/p>\n

MALT Lymphoma Market Companies<\/strong><\/p>\n

Regeneron Pharmaceuticals<\/p>\n

Kami Maddocks in collaboration with Novartis<\/p>\n

Kami Maddocks in collaboration with Pharmacyclics LLC.<\/p>\n

Northwestern University in collaboration with Seattle Genetics, Inc.<\/p>\n

 <\/p>\n

MALT Lymphoma Market Insights<\/strong><\/p>\n

In Europe, the Maastricht IV guidelines (2016) recommended that first-line and second-line therapies should be clarithromycin-based regimens and bismuth-based quadruple therapy (PPI, Bismuth, Tetracycline and a Nitroimidazole for 10–14 days), respectively. If those two regimens fail, a third-line therapy with a fluoroquinolone-based regimen (PPI, amoxicillin, and levofloxacin) is recommended. Besides, hybrid therapies and sequential therapies are missing from the European recommendations.<\/p>\n

 <\/p>\n

MALT Lymphoma Market Report Scope<\/strong><\/p>\n